Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Markus Maeurer and Alimuddin Zumla.
Markus Maeurer
Connection Strength
10.046
Alimuddin Zumla
  1. Host-directed therapies for COVID-19. Curr Opin Pulm Med. 2021 05 01; 27(3):205-209.
    View in: PubMed
    Score: 0.943
  2. Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies. Int J Infect Dis. 2020 Jul; 96:431-439.
    View in: PubMed
    Score: 0.882
  3. Reducing mortality from 2019-nCoV: host-directed therapies should be an option. Lancet. 2020 02 22; 395(10224):e35-e36.
    View in: PubMed
    Score: 0.866
  4. B cells or T cells in TB: a continuing conundrum. Lancet Respir Med. 2018 04; 6(4):237-238.
    View in: PubMed
    Score: 0.761
  5. Host-directed therapies for multidrug resistant tuberculosis. Int J Mycobacteriol. 2016 Dec; 5 Suppl 1:S21-S22.
    View in: PubMed
    Score: 0.692
  6. Host-directed therapies for improving poor treatment outcomes associated with the middle east respiratory syndrome coronavirus infections. Int J Infect Dis. 2015 Nov; 40:71-4.
    View in: PubMed
    Score: 0.638
  7. Bacille Calmette-Guérin (BCG) vaccine and potential cross-protection against SARS-CoV-2 infection - Assumptions, knowns, unknowns and need for developing an accurate scientific evidence base. Int J Infect Dis. 2021 Dec; 113 Suppl 1:S78-S81.
    View in: PubMed
    Score: 0.234
  8. World Tuberculosis Day 2021 Theme - 'The Clock is Ticking' - and the world is running out of time to deliver the United Nations General Assembly commitments to End TB due to the COVID-19 pandemic. Int J Infect Dis. 2021 12; 113 Suppl 1:S1-S6.
    View in: PubMed
    Score: 0.234
  9. COVID-19 and tuberculosis-threats and opportunities. Int J Tuberc Lung Dis. 2020 08 01; 24(8):757-760.
    View in: PubMed
    Score: 0.224
  10. Mortality in COVID-19 disease patients: Correlating the association of major histocompatibility complex (MHC) with severe acute respiratory syndrome 2 (SARS-CoV-2) variants. Int J Infect Dis. 2020 Sep; 98:454-459.
    View in: PubMed
    Score: 0.223
  11. Toning down the 2019-nCoV media hype-and restoring hope. Lancet Respir Med. 2020 03; 8(3):230-231.
    View in: PubMed
    Score: 0.217
  12. Immunometabolism and Pulmonary Infections: Implications for Protective Immune Responses and Host-Directed Therapies. Front Microbiol. 2019; 10:962.
    View in: PubMed
    Score: 0.205
  13. Latent TB Infection (LTBI) - Mycobacterium tuberculosis pathogenesis and the dynamics of the granuloma battleground. Int J Infect Dis. 2019 Mar; 80S:S58-S61.
    View in: PubMed
    Score: 0.203
  14. Improving treatment outcomes for MDR-TB - Novel host-directed therapies and personalised medicine of the future. Int J Infect Dis. 2019 Mar; 80S:S62-S67.
    View in: PubMed
    Score: 0.201
  15. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Lancet Infect Dis. 2018 07; 18(7):e183-e198.
    View in: PubMed
    Score: 0.190
  16. Taking forward the Stop TB Partnership and World Health Organization Joint Theme for World TB Day March 24th 2018 - "Wanted: Leaders for a TB-Free World. You can make history. End TB". Int J Infect Dis. 2018 03; 68:122-124.
    View in: PubMed
    Score: 0.190
  17. Evaluation of the efficacy of valproic acid and suberoylanilide hydroxamic acid (vorinostat) in enhancing the effects of first-line tuberculosis drugs against intracellular Mycobacterium tuberculosis. Int J Infect Dis. 2018 Apr; 69:78-84.
    View in: PubMed
    Score: 0.189
  18. IL-7d5 protein is expressed in human tissues and induces expression of the oxidized low density lipoprotein receptor 1 (OLR1) in CD14+ monocytes. Int J Infect Dis. 2017 Jun; 59:29-36.
    View in: PubMed
    Score: 0.177
  19. World TB Day 2017: Advances, Challenges and Opportunities in the "End-TB" Era. Int J Infect Dis. 2017 03; 56:1-5.
    View in: PubMed
    Score: 0.176
  20. Strong anti-Epstein Barr virus (EBV) or cytomegalovirus (CMV) cellular immune responses predict survival and a favourable response to anti-tuberculosis therapy. Int J Infect Dis. 2017 Mar; 56:136-139.
    View in: PubMed
    Score: 0.176
  21. Immune recognition surface construction of Mycobacterium tuberculosis epitope-specific antibody responses in tuberculosis patients identified by peptide microarrays. Int J Infect Dis. 2017 Mar; 56:155-166.
    View in: PubMed
    Score: 0.176
  22. Peptide microarray-based characterization of antibody responses to host proteins after bacille Calmette-Guérin vaccination. Int J Infect Dis. 2017 Mar; 56:140-154.
    View in: PubMed
    Score: 0.176
  23. Mycobacterium tuberculosis proteins involved in cell wall lipid biosynthesis improve BCG vaccine efficacy in a murine TB model. Int J Infect Dis. 2017 Mar; 56:274-282.
    View in: PubMed
    Score: 0.176
  24. Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm. Int J Infect Dis. 2017 Mar; 56:221-228.
    View in: PubMed
    Score: 0.176
  25. Humoral immune profiling of mycobacterial antigen recognition in sarcoidosis and Löfgren's syndrome using high-content peptide microarrays. Int J Infect Dis. 2017 Mar; 56:167-175.
    View in: PubMed
    Score: 0.176
  26. Taking forward a 'One Health' approach for turning the tide against the Middle East respiratory syndrome coronavirus and other zoonotic pathogens with epidemic potential. Int J Infect Dis. 2016 Jun; 47:5-9.
    View in: PubMed
    Score: 0.168
  27. Why healthcare workers are sick of TB. Int J Infect Dis. 2015 Mar; 32:147-51.
    View in: PubMed
    Score: 0.154
  28. Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options. Lancet Infect Dis. 2014 Nov; 14(11):1136-1149.
    View in: PubMed
    Score: 0.149
  29. The Hajj pilgrimage and surveillance for Middle East Respiratory syndrome coronavirus in pilgrims from African countries. Trop Med Int Health. 2014 Jul; 19(7):838-40.
    View in: PubMed
    Score: 0.145
  30. Looking for pathways related to COVID-19: confirmation of pathogenic mechanisms by SARS-CoV-2-host interactome. Cell Death Dis. 2021 08 12; 12(8):788.
    View in: PubMed
    Score: 0.060
  31. Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct Target Ther. 2021 02 10; 6(1):58.
    View in: PubMed
    Score: 0.058
  32. The unbalanced p53/SIRT1 axis may impact lymphocyte homeostasis in COVID-19 patients. Int J Infect Dis. 2021 Apr; 105:49-53.
    View in: PubMed
    Score: 0.058
  33. COVID-19 disease-Temporal analyses of complete blood count parameters over course of illness, and relationship to patient demographics and management outcomes in survivors and non-survivors: A longitudinal descriptive cohort study. PLoS One. 2020; 15(12):e0244129.
    View in: PubMed
    Score: 0.058
  34. Different Innate and Adaptive Immune Responses to SARS-CoV-2 Infection of Asymptomatic, Mild, and Severe Cases. Front Immunol. 2020; 11:610300.
    View in: PubMed
    Score: 0.057
  35. An Inflammatory Profile Correlates With Decreased Frequency of Cytotoxic Cells in Coronavirus Disease 2019. Clin Infect Dis. 2020 11 19; 71(16):2272-2275.
    View in: PubMed
    Score: 0.057
  36. Lessons from the COVID-19 Pandemic-Unique Opportunities for Unifying, Revamping and Reshaping Epidemic Preparedness of Europe's Public Health Systems. Int J Infect Dis. 2020 12; 101:361-366.
    View in: PubMed
    Score: 0.057
  37. Early expansion of myeloid-derived suppressor cells inhibits SARS-CoV-2 specific T-cell response and may predict fatal COVID-19 outcome. Cell Death Dis. 2020 10 27; 11(10):921.
    View in: PubMed
    Score: 0.057
  38. Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. Signal Transduct Target Ther. 2020 08 27; 5(1):172.
    View in: PubMed
    Score: 0.056
  39. Immune responses during COVID-19 infection. Oncoimmunology. 2020 08 25; 9(1):1807836.
    View in: PubMed
    Score: 0.056
  40. Single-cell landscape of immunological responses in patients with COVID-19. Nat Immunol. 2020 09; 21(9):1107-1118.
    View in: PubMed
    Score: 0.056
  41. Immunological and inflammatory profiles in mild and severe cases of COVID-19. Nat Commun. 2020 07 08; 11(1):3410.
    View in: PubMed
    Score: 0.056
  42. COVID-19: viral-host interactome analyzed by network based-approach model to study pathogenesis of SARS-CoV-2 infection. J Transl Med. 2020 06 10; 18(1):233.
    View in: PubMed
    Score: 0.055
  43. Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19). Cell Death Differ. 2020 11; 27(11):3196-3207.
    View in: PubMed
    Score: 0.055
  44. Non-Steroidal Anti-inflammatory Drugs As Host-Directed Therapy for Tuberculosis: A Systematic Review. Front Immunol. 2017; 8:772.
    View in: PubMed
    Score: 0.045
  45. Tuberculosis associated mortality in a prospective cohort in Sub Saharan Africa: Association with HIV and antiretroviral therapy. Int J Infect Dis. 2017 Mar; 56:39-44.
    View in: PubMed
    Score: 0.044
  46. The global dynamics of diabetes and tuberculosis: the impact of migration and policy implications. Int J Infect Dis. 2017 Mar; 56:45-53.
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.